Liquid chromatography–mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase-Reference-Cited by-同舟云学术

Liquid chromatography–mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase

Published:2008-09 Issue:1-2 Volume:872 Page:141-147
ISSN:1570-0232
Container-title:Journal of Chromatography B
language:en
Short-container-title:Journal of Chromatography B

Author:

Parise Robert A.,Shawaqfeh Mohammad,Egorin Merrill J.,Beumer Jan H.

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference10 articles.

1. PARP inhibitors for cancer therapy

2. J. Low, Solicitation for preclinical studies (ABT-888 PARP inhibitor) CTEP rapid communication, 2005.

3. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620);Breast Cancer Research and Treatment;2023-02-28

2. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer;Cancer Chemotherapy and Pharmacology;2022-04-18

3. A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies;Cancer Chemotherapy and Pharmacology;2021-10-20

4. Development and validation of an LC–MS/MS generic assay platform for small molecule drug bioanalysis;Journal of Pharmaceutical and Biomedical Analysis;2021-09

5. A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients;The Journal of Clinical Pharmacology;2021-06-19